Eli Lilly's Phase 3 study results for orforglipron, a new GLP-1 pill for weight loss and diabetes, show promising outcomes. This pill is similar to well-known injectables like Ozempic but more accessible due to its oral format. It targets a significant global obesity crisis, with Lilly aiming for FDA approval by late 2025. The pill promises to reach a broader audience by providing a weight-loss solution for individuals averse to injections, thereby potentially revolutionizing the treatment landscape.
"Most importantly, when you look at the global need, we expect that there are more than one billion people across the globe that are suffering from obesity; there is no way that we can meet those demands with injectable treatments today."
"Orforglipron will likely unlock a much wider market, bringing the benefits of groundbreaking weight-loss drugs to people who can't, or don't want to, use injections."
Collection
[
|
...
]